738 related articles for article (PubMed ID: 26847392)
1. Tumour necrosis factor-α inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis: a systematic review and economic evaluation.
Corbett M; Soares M; Jhuti G; Rice S; Spackman E; Sideris E; Moe-Byrne T; Fox D; Marzo-Ortega H; Kay L; Woolacott N; Palmer S
Health Technol Assess; 2016 Feb; 20(9):1-334, v-vi. PubMed ID: 26847392
[TBL] [Abstract][Full Text] [Related]
2. Adalimumab, etanercept and infliximab for the treatment of ankylosing spondylitis: a systematic review and economic evaluation.
McLeod C; Bagust A; Boland A; Dagenais P; Dickson R; Dundar Y; Hill RA; Jones A; Mujica Mota R; Walley T
Health Technol Assess; 2007 Aug; 11(28):1-158, iii-iv. PubMed ID: 17651658
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of TNFα blockers in patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis: a meta-analysis.
Callhoff J; Sieper J; Weiß A; Zink A; Listing J
Ann Rheum Dis; 2015 Jun; 74(6):1241-8. PubMed ID: 24718959
[TBL] [Abstract][Full Text] [Related]
4. TNF-alpha inhibitors for ankylosing spondylitis.
Maxwell LJ; Zochling J; Boonen A; Singh JA; Veras MM; Tanjong Ghogomu E; Benkhalti Jandu M; Tugwell P; Wells GA
Cochrane Database Syst Rev; 2015 Apr; (4):CD005468. PubMed ID: 25887212
[TBL] [Abstract][Full Text] [Related]
5. Golimumab for the treatment of ankylosing spondylitis: a NICE single technology appraisal.
Armstrong N; Joore M; van Asselt T; Misso K; Manning N; Tomini F; Kleijnen J; Riemsma R
Pharmacoeconomics; 2013 May; 31(5):415-25. PubMed ID: 23580355
[TBL] [Abstract][Full Text] [Related]
6. A systematic review and economic evaluation of the use of tumour necrosis factor-alpha (TNF-α) inhibitors, adalimumab and infliximab, for Crohn's disease.
Dretzke J; Edlin R; Round J; Connock M; Hulme C; Czeczot J; Fry-Smith A; McCabe C; Meads C
Health Technol Assess; 2011 Feb; 15(6):1-244. PubMed ID: 21291629
[TBL] [Abstract][Full Text] [Related]
7. A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness.
Chen YF; Jobanputra P; Barton P; Jowett S; Bryan S; Clark W; Fry-Smith A; Burls A
Health Technol Assess; 2006 Nov; 10(42):iii-iv, xi-xiii, 1-229. PubMed ID: 17049139
[TBL] [Abstract][Full Text] [Related]
8. Enzyme-linked immunosorbent assays for monitoring TNF-alpha inhibitors and antibody levels in people with rheumatoid arthritis: a systematic review and economic evaluation.
Tikhonova IA; Yang H; Bello S; Salmon A; Robinson S; Hemami MR; Dodman S; Kharechko A; Haigh RC; Jani M; McDonald TJ; Hoyle M
Health Technol Assess; 2021 Feb; 25(8):1-248. PubMed ID: 33555998
[TBL] [Abstract][Full Text] [Related]
9. Non-steroidal anti-inflammatory drugs (NSAIDs) for axial spondyloarthritis (ankylosing spondylitis and non-radiographic axial spondyloarthritis).
Kroon FP; van der Burg LR; Ramiro S; Landewé RB; Buchbinder R; Falzon L; van der Heijde D
Cochrane Database Syst Rev; 2015 Jul; 2015(7):CD010952. PubMed ID: 26186173
[TBL] [Abstract][Full Text] [Related]
10. Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis: a systematic review and economic evaluation.
Rodgers M; Epstein D; Bojke L; Yang H; Craig D; Fonseca T; Myers L; Bruce I; Chalmers R; Bujkiewicz S; Lai M; Cooper N; Abrams K; Spiegelhalter D; Sutton A; Sculpher M; Woolacott N
Health Technol Assess; 2011 Feb; 15(10):i-xxi, 1-329. PubMed ID: 21333232
[TBL] [Abstract][Full Text] [Related]
11. Including adverse drug events in economic evaluations of anti-tumour necrosis factor-α drugs for adult rheumatoid arthritis: a systematic review of economic decision analytic models.
Heather EM; Payne K; Harrison M; Symmons DP
Pharmacoeconomics; 2014 Feb; 32(2):109-34. PubMed ID: 24338344
[TBL] [Abstract][Full Text] [Related]
12. Certolizumab pegol and secukinumab for treating active psoriatic arthritis following inadequate response to disease-modifying antirheumatic drugs: a systematic review and economic evaluation.
Corbett M; Chehadah F; Biswas M; Moe-Byrne T; Palmer S; Soares M; Walton M; Harden M; Ho P; Woolacott N; Bojke L
Health Technol Assess; 2017 Oct; 21(56):1-326. PubMed ID: 28976302
[TBL] [Abstract][Full Text] [Related]
13. An appraisal of golimumab in the treatment of severe, active nonradiographic axial spondyloarthritis.
Paccou J; Flipo RM
Drug Des Devel Ther; 2016; 10():2255-62. PubMed ID: 27468228
[TBL] [Abstract][Full Text] [Related]
14. Efficiency of adalimumab, etanercept and infliximab in ankylosing spondylitis in clinical practice.
Escudero-Vilaplana V; Ramírez-Herráiz E; Alañón-Plaza E; Trovato-López N; García-Vicuña R; Carreño-Pérez L; Morell-Baladrón A; Sanjurjo-Sáez M
Int J Clin Pharm; 2015 Oct; 37(5):808-14. PubMed ID: 25910480
[TBL] [Abstract][Full Text] [Related]
15. Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for the treatment of rheumatoid arthritis not previously treated with disease-modifying antirheumatic drugs and after the failure of conventional disease-modifying antirheumatic drugs only: systematic review and economic evaluation.
Stevenson M; Archer R; Tosh J; Simpson E; Everson-Hock E; Stevens J; Hernandez-Alava M; Paisley S; Dickinson K; Scott D; Young A; Wailoo A
Health Technol Assess; 2016 Apr; 20(35):1-610. PubMed ID: 27140438
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of biological DMARDs: a systematic literature review informing the 2022 update of the ASAS-EULAR recommendations for the management of axial spondyloarthritis.
Webers C; Ortolan A; Sepriano A; Falzon L; Baraliakos X; Landewé RBM; Ramiro S; van der Heijde D; Nikiphorou E
Ann Rheum Dis; 2023 Jan; 82(1):130-141. PubMed ID: 36270657
[TBL] [Abstract][Full Text] [Related]
17. Sustained efficacy, safety and patient-reported outcomes of certolizumab pegol in axial spondyloarthritis: 4-year outcomes from RAPID-axSpA.
van der Heijde D; Dougados M; Landewé R; Sieper J; Maksymowych WP; Rudwaleit M; Van den Bosch F; Braun J; Mease PJ; Kivitz AJ; Walsh J; Davies O; Bauer L; Hoepken B; Peterson L; Deodhar A
Rheumatology (Oxford); 2017 Sep; 56(9):1498-1509. PubMed ID: 28498975
[TBL] [Abstract][Full Text] [Related]
18. Comparison of non-radiographic axial spondyloarthritis and ankylosing spondylitis patients--baseline characteristics, treatment adherence, and development of clinical variables during three years of anti-TNF therapy in clinical practice.
Wallman JK; Kapetanovic MC; Petersson IF; Geborek P; Kristensen LE
Arthritis Res Ther; 2015 Dec; 17():378. PubMed ID: 26703005
[TBL] [Abstract][Full Text] [Related]
19. Risk of serious infections in biological treatment of patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis: a meta-analysis.
Wang S; He Q; Shuai Z
Clin Rheumatol; 2018 Feb; 37(2):439-450. PubMed ID: 29290076
[TBL] [Abstract][Full Text] [Related]
20. Cost-Effectiveness of Treatment Strategies with Biologics in Accordance with Treatment Guidelines for Ankylosing Spondylitis: A Patient-Level Model.
Le QA; Kang JH; Lee S; Delevry D
J Manag Care Spec Pharm; 2020 Oct; 26(10):1219-1231. PubMed ID: 32996395
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]